Molecular Partners Publishes Invitation to Annual General Meeting 2022
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) has announced the details of its Annual General Meeting (AGM) scheduled for April 13, 2022, at 2 PM CET. The meeting will be held virtually due to ongoing pandemic concerns, allowing shareholders to participate only through written or electronically submitted instructions to an independent proxy. Key upcoming financial events include the Interim Management Statement Q1 2022 on May 12, 2022, and Half-year results 2022 on August 25, 2022. Molecular Partners is focused on developing DARPin therapeutics for various medical applications.
- Announcement of the Annual General Meeting provides transparency and engagement with shareholders.
- Molecular Partners is advancing innovative DARPin therapeutics, which position the company favorably in the biotech sector.
- Company has formed partnerships with leading pharmaceutical companies, enhancing its market position and development capability.
- None.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2022.
The Annual General Meeting will be held on Wednesday, April 13, 2022, 2pm CET, at the registered office of Molecular Partners AG, Wagistrasse 14, 8952 Schlieren, Switzerland.
In deference to the ongoing pandemic situation, the Board of Directors of Molecular Partners AG has decided to conduct the Annual General Meeting without the physical presence of shareholders. As a result, shareholders of Molecular Partners AG may exercise their rights at the Annual General Meeting exclusively via written or electronically submitted instructions to the independent proxy.
- Invitation to the Annual General Meeting 2022 with the corresponding agenda items
- Einladung zur Generalversammlung 2022 mit den zugehörigen Traktandenpunkten
Financial calendar
| April 13, 2022 | Annual General Meeting |
| May 12, 2022 | Interim Management Statement Q1 2022 |
| August 25, 2022 | Half-year results 2022 (unaudited) |
| October 27, 2022 | Interim Management Statement Q3 2022 |
The latest timing of the above events can always be viewed on the investor section of the website.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of infectious disease oncology, and ophthalmology, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs
FAQ
When will the Annual General Meeting for Molecular Partners AG be held?
How will shareholders participate in the Molecular Partners AG Annual General Meeting?
What are the important financial dates for Molecular Partners AG in 2022?
What is the focus of Molecular Partners AG in biotech?
